On November 8, 2024, the Food and Drug Administration sanctioned obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-targeted genetically engineered autologous CAR T cell therapy, for people with...
cd19-targeted-therapy
CAR T Cell therapy in KoreaCAR T cell therapy is an advanced cancer treatment that has gained significant momentum in South Korea. It involves genetically modifying a patient’s T cells to recognize ...
cd19-targeted-therapy
Introduction
CAR T cell therapy has been a game-changer in the treatment of certain lymphomas, more so in patients relapsing or refractory to conventional therapies. This has been quite successful in...
cd19-targeted-therapy
Introduction
CAR T cell therapy is the breakthrough treatment against various kinds of leukemias, particularly B-cell ALL. In this treatment, genetically modified T cells are specifically designed to...
cd19-targeted-therapy